INDIVIOR UK LIMITED

• ◆

  6 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

Figures converted to GBP from USD at 0.748 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +9.3%

  £499,625,477 → £546,298,871

• Cash

  -66.1%

  £27,523,361 → £9,341,407

• Net assets

  +27%

  £245,013,830 → £311,158,705

• Employees

  +8.5%

  177 → 192

• Operating profit

  +11.5%

  £83,085,894 → £92,641,100

• Profit before tax

  +12.4%

  £94,776,108 → £106,575,465

• Wages

  +3%

  £20,107,647 → £20,710,922

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. INDIVIOR UK LIMITED 2015-07-01 → present
2. RB PHARMACEUTICALS LIMITED 2010-03-09 → 2015-07-01

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“These financial statements are prepared using the going concern basis of accounting. The Company's business activities, together with the factors likely to affect its future development and position, are set out in the Business Review section of the Strategic Report on page 2. The Company has net assets of $416,237k (2023: $327,755k). The Directors intend to continue the business operations in the foreseeable future.”

Group structure

1. INDIVIOR UK LIMITED · parent
   1. Indivior Canada Ltd 100% · Canada · Trading Company
   2. Indivior Deutschland GmbH 100% · Germany · Trading Company
   3. Indivior España S.L.U. 100% · Spain · Trading Company
   4. Indivior EU Limited 100% · England & Wales · Trading Company
   5. Indivior Europe Limited 100% · Ireland · Dormant Company
   6. Indivior France SAS 100% · France · Trading Company
   7. Indivior Israel Ltd 100% · Israel · Trading Company
   8. Indivior Italia S.r.l. 100% · Italy · Trading Company
   9. Indivior Nordics ApS 100% · Denmark · Trading Company
   10. Opiant Pharmaceuticals UK Limited 100% · England & Wales · Dormant Company
   11. Indivior Schweiz AG 100% · Switzerland · Trading Company

Significant events

• “Effective 1 January 2024, the functional currency of Indivior UK Limited changed from pound sterling to U.S. dollar (USD).”
• “In June 2024, development of the remaining Opiant UK pipeline project addressing cannabis-use disorder via nasal inhaler was discontinued.”
• “On 9 July 2024, the Group announced the discontinuation of marketing and promotion for PERSERIS.”
• “On 4 September 2024, Aelis Farma announced that its clinical Phase 2B study with AEF0117 in participants with cannabis use disorder did not demonstrate the anticipated results.”
• “During the first quarter of 2025, the Group identified an error in the methodology used to accrue for Indivior's share of the annual U.S. fee imposed on drug manufacturers ... resulting in Indivior UK Limited being overcharged by $9,500k relating to prior years.”
• “In August 2025, the Group announced actions related to an initiative intended to maximise the potential of Indivior PLC's business...”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

17

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

6

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.